65. Primary immunodeficiency Disease details / Clinical trials / Drug dev / DR info

16, Cutaquig   
   Ottawa Hospital Research Institute
      2018   Phase 4   NCT03677557   Canada;
2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID   
   IntraBio Ltd
      2020   Phase 2   EUCTR2018-004407-39-DE   Germany;Spain;United Kingdom;United States;
36-482-Hyaluronoglucosaminidase PH20 (rHuPH20)   
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
A10BK03   
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium;
ADA PBSC   
   National Human Genome Research Institute (NHGRI)
      1990   -   NCT00001255   United States;
ADA Umbilical Cord Blood Cells   
   National Human Genome Research Institute (NHGRI)
      1990   -   NCT00001255   United States;
ADA gene transfer   
   Donald B. Kohn, M.D.
      2008   Phase 2   NCT00794508   United States;
AProArt   
   University of California, San Francisco
      2018   Phase 1/Phase 2   NCT03538899   United States;
AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR   
   GENETHON
      2013   -   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom;
   Genethon
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom;
Abatacept   
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT04925375   United States;
   Emory University
      2014   Phase 1   NCT01917708   United States;
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany;
Acoziborole   
   Drugs for Neglected Diseases
      2021   Phase 2/Phase 3   NCT05256017   Congo, The Democratic Republic of the;Guinea;
Acoziborole (SCYX-7158)   
   Drugs for Neglected Diseases
      2016   Phase 2/Phase 3   NCT03087955   Congo, The Democratic Republic of the;Guinea;
Adagen   
   Leadiant Biosciences, Inc.
      2014   Phase 3   NCT01420627   United States;
Administration of drug (Interferon-gamma 1-b) subcutaneously   
   University of Colorado, Denver
      2016   Phase 1   NCT02609932   United States;
Adverse Reactions of Gammagard subcutaneously at Week 12   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Adverse Reactions of Gammagard subcutaneously at Week 24   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Adverse Reactions of Gammagard subcutaneously at Week 36   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Adverse Reactions of Gammagard subdermally at Week 12   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Adverse Reactions of Gammagard subdermally at Week 24   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Adverse Reactions of Gammagard subdermally at Week 36   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Alefacept   
   Emory University
      2010   -   NCT01319851   United States;
Alemtuzumab   
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States;
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2012   -   NCT01652092   United States;
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Early Phase 1   NCT03910452   United States;
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Alentuzumab (Campath)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2015   Phase 1/Phase 2   NCT02629120   United States;
Allo BMT   
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States;
Allogeneic Bone Marrow Transplantation   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
      2006   Phase 2   NCT00358657   United States;
      1997   Phase 1   NCT00008450   United States;
Allogeneic HSC   
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States;
Allogeneic HSCT   
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
Allogeneic bone marrow transplantation   
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2005   Phase 1   NCT00295971   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Allogeneic hematopoietic stem cell transplantation   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2005   Phase 1   NCT00295971   United States;
Allogeneic peripheral blood stem cell   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Early Phase 1   NCT03910452   United States;
Anti-CD45   
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States;
Anti-thymocyte globulin   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2000   Phase 2/Phase 3   NCT00176878   United States;
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Anti-thymocyte globulin (rabbit)   
   St. Jude Children's Research Hospital
      2021   Phase 1/Phase 2   NCT03597594   United States;
Antithymocyte globulin   
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Argininhydrochlorid   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Asceniv™   
   ADMA Biologics, Inc.
      2022   Phase 4   NCT05070455   -
Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene   
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom;
      2012   Phase 1;Phase 2   EUCTR2010-024253-36-GB   United Kingdom;
Autologous CD34+ cell transduced with G2SCID vector   
   David Williams
      2018   Phase 1/Phase 2   NCT03311503   United Kingdom;United States;
Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy   
   GENETHON
      -   Phase 1;Phase 2   EUCTR2009-011152-22-FR   France;
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)   
   Orchard Therapeutics
      2019   -   NCT04049084   United Kingdom;United States;
B-Lymphocyte Stimulator (BLyS)   
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00024934   United States;
BMS-188667   
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany;
BPX-501 T cells   
   Bellicum Pharmaceuticals
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
BT090   
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary;
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary;
BT524   
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon;
BT595   
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States;
BT681   
   Biotest AG
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary;
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary;
BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI   
   Orchard Therapeutics (Europe) Ltd
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy;
Baclofen   
   Johns Hopkins University
      2007   Early Phase 1   NCT00640003   United States;
Bacteriophage   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States;
Benznidazole   
   Population Health Research Institute
      2004   Phase 3   NCT00123916   Argentina;Bolivia;Brazil;Canada;Colombia;El Salvador;
   Universidad Autónoma de Bucaramanga
      2015   Phase 2/Phase 3   NCT02369978   Colombia;
Biological sampling   
   Imagine Institute
      2015   -   NCT02909244   France;
Bivigam   
   ADMA Biologics, Inc.
      2016   -   NCT03037359   United States;
Blood Draw   
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
Blood Sample   
   Koneti Rao
      2008   Phase 1/Phase 2   NCT00605657   United States;
Busilvex   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland;
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland;
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland;
   medac GmbH
      2015   Phase 2   NCT02349906   Austria;Czech Republic;Czechia;Germany;Italy;Poland;
      2015   -   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland;
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland;
Busulfan   
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States;
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom;
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom;
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
      2000   Phase 2/Phase 3   NCT00176878   United States;
   Michael Pulsipher, MD
      2018   Phase 2   NCT03619551   United States;
   National Center for Child Health and Development
      2017   -   JPRN-UMIN000030647   Japan;
      2016   -   JPRN-UMIN000022688   Japan;
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT04370795   United States;
      2019   Early Phase 1   NCT03910452   United States;
      2014   Phase 1/Phase 2   NCT02282904   United States;
      2012   Phase 1/Phase 2   NCT03315078   United States;
      2012   Phase 1/Phase 2   NCT01306019   United States;
   Orchard Therapeutics
      2016   Phase 1/Phase 2   NCT02999984   United States;
      2013   Phase 1/Phase 2   NCT01852071   United States;
   Sakaguchi Hirotoshi
      2018   Phase 2   JPRN-jRCTs031180398   Japan;None (Japan only);
   Seoul National University Hospital
      2011   Phase 1/Phase 2   NCT01338675   Korea, Republic of;
   St. Jude Children's Research Hospital
      2021   Phase 1/Phase 2   NCT03597594   United States;
      2016   Phase 1/Phase 2   NCT01512888   United States;
   University of California, San Francisco
      2018   Phase 1/Phase 2   NCT03538899   United States;
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Busulfan IV   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2015   Phase 1/Phase 2   NCT02629120   United States;
Busulfan test dose   
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
Busulfan, Cyclophosphamide, ATG, GCSF   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Busulfan, Fludarabine and ATG   
   Emory University
      2004   Phase 1/Phase 2   NCT00228852   United States;
Busulfan, Fludarabine, ATG, TLI   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
C1 ESTERASE INHIBITOR (HUMAN)   
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2020   Phase 2   EUCTR2019-001693-28-DE   Belarus;Germany;Russian Federation;Ukraine;
C1 Esterase Inhibitor Human   
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2020   Phase 2   EUCTR2019-001693-28-DE   Belarus;Germany;Russian Federation;Ukraine;
C1 inhibitor   
   HAE Global Registry Foundation
      2017   -   NCT03828279   Italy;
C1 inhibitor concentrate   
   Sanquin
      2005   Phase 2   NCT00119431   Netherlands;
C1-esterase inhibitor [recombinant] (C1-INH-R)   
   IMMUNOe Research Centers
      2018   Phase 4   NCT03576469   United States;
CD3/CD19 neg allogeneic BMT   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03330795   United States;
CD3/CD19 negative allogeneic hematopoietic stem cells   
   Paul Szabolcs
      2013   Phase 1/Phase 2   NCT01852370   United States;
CD34 Stem Cell Selection Therapy   
   Diane George
      2013   Phase 1/Phase 2   NCT01966367   United States;
CD34+   
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 2   NCT01856582   United States;
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 1/Phase 2   NCT03315078   United States;
CD34+ cells transduced with ADA retrovir   
   National Human Genome Research Institute (NHGRI)
      2001   Phase 1   NCT00018018   United States;
CD34+CELLS   
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States;
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain;
CDZ173   
   NOVARTIS PHARMA SERVICES AG
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IT   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
   Novartis Pharma Services AG
      2021   Phase 2;Phase 3   EUCTR2016-000468-41-FR   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2016-000468-41-GB   Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-NL   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-CZ   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
   Novartis Pharmaceuticals
      2015   Phase 2/Phase 3   NCT02435173   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
   Pharming Technologies B.V.
      -   Phase 2;Phase 3   EUCTR2016-000468-41-DE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
CL20-i4-EF1a-h?c-OPT   
   St. Jude Children's Research Hospital
      2016   Phase 1/Phase 2   NCT01512888   United States;
CT Scan   
   Koneti Rao
      2008   Phase 1/Phase 2   NCT00605657   United States;
CUTAQUIG   
   Octapharma
      2019   Phase 3   NCT03939533   United States;
CUVITRU   
   Baxalta now part of Shire
      2018   -   NCT03716700   Canada;
Campath -1H   
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States;
Campath 1H   
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Campath, Fludarabine, Cyclophosphamide   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Catapresan 75, Tabletten   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Cell processing for TCRabeta+/CD19+ depletion   
   Michael Pulsipher, MD
      2018   Phase 2   NCT03619551   United States;
Cell processing for TCRaß+/CD19+ depletion   
   Michael Pulsipher, MD
      2018   Phase 2   NCT03619551   United States;
Chemotherapy, intrathecal chemotherapy, steroid therapy   
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States;
Chrono Super PID then Generic Syringe-Gammanorm   
   Octapharma
      2015   Phase 4   NCT02503293   Australia;Germany;Italy;United Kingdom;
CliniMACS   
   St. Jude Children's Research Hospital
      2021   Phase 1/Phase 2   NCT03597594   United States;
CliniMACS® CD34 Reagent System cell sorter device   
   University of California, San Francisco
      2018   Phase 1/Phase 2   NCT03538899   United States;
CliniMacs   
   St. Jude Children's Research Hospital
      2016   Phase 1/Phase 2   NCT01512888   United States;
Clonidinhydrochlorid   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Collection of samples   
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Conjugated pneumococcal vaccine (Prevenar)   
   Institute of Child Health
      2006   Phase 3   NCT00656409   United Kingdom;
Continuous Glucose Monitor   
   Washington University School of Medicine
      2020   -   NCT04275479   United States;
Cryopreserved EFS-ADA LV transduced patient CD34+ cells   
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom;
Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells   
   Great Ormond Street Hospital for Children NHS Trust
      2018   Phase 1   EUCTR2018-000673-68-GB   United Kingdom;
Cultured Thymus Tissue   
   M. Louise Markert
      2010   -   NCT01220531   United States;
Cultured Thymus Tissue Implantation (CTTI)   
   M. Louise Markert
      2004   Phase 2   NCT00576836   United States;
Cultured Thymus Tissue for Implantation (CTTI)   
   M. Louise Markert
      2005   Phase 1/Phase 2   NCT00579527   United States;
      1991   Phase 2   NCT00576407   United States;
Cuvitru   
   Baxalta now part of Shire
      2017   Phase 4   NCT03116347   Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
Cuvitru 200 mg/ml solution for subcutaneous injection   
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Cyclophosphamide   
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States;
   Capital Research Institute of Pediatrics
      2015   -   NCT03198195   -
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
      2015   -   JPRN-UMIN000019532   Japan;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2012   -   NCT01652092   United States;
      2007   Phase 2/Phase 3   NCT00455312   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Early Phase 1   NCT03910452   United States;
      2015   Phase 1/Phase 2   NCT02629120   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Cyclophosphamide (Cytoxan)   
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
Cyclophosphamide 30   
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
Cyclophosphamide 40   
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
Cyclophosphamide Dose Level 1   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 2   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 3   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 4   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide post transplant   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States;
Cyclosporine   
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States;
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00008450   United States;
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Cyclosporins   
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
DB289   
   Immtech Pharmaceuticals, Inc
      2003   Phase 2   NCT00803933   Congo;
      2001   Phase 2   NCT00802594   Angola;Congo;
DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.   
   ERYDEL S.P.A.
      2016   Phase 3   EUCTR2015-005241-31-IT   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
   EryDel S.p.A.
      2020   Phase 3   EUCTR2018-000338-36-NO   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-000338-36-GB   Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000338-36-ES   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000338-36-DE   Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000338-36-BE   Australia;Belgium;Germany;India;Israel;Poland;Spain;United States;
      2016   Phase 3   EUCTR2015-005241-31-NO   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005241-31-ES   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005241-31-DE   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005241-31-BE   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000338-36-PL   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
      -   Phase 3   EUCTR2015-005241-31-PL   Australia;Belgium;Costa Rica;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Daclizumab   
   M. Louise Markert
      2005   Phase 1/Phase 2   NCT00579527   United States;
Danazol   
   Boston Children's Hospital
      2009   Phase 1/Phase 2   NCT01001598   United States;
   The University of Queensland
      2021   Phase 2   NCT04638517   Australia;
Data collection   
   Paul Szabolcs
      2020   -   NCT04528355   United States;
Depletion in CD45RA graft donor   
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 2   NCT02737384   France;
Dexametasone Fosfato Sodico   
   ERYDEL S.P.A.
      2016   Phase 3   EUCTR2015-005241-31-IT   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Dexamethasone 21-dihydrogen phosphate   
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2005-003201-81-DE   Germany;
Dexamethasone sodium phosphate (soluzione 25mg/ml)   
   ERYDEL S.P.A.
      2021   Phase 3   EUCTR2018-000338-36-IT   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
Dexamethasone, procarbazine   
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States;
Dextrose, in Water   
   Grifols Therapeutics Inc.
      2002   Phase 3   NCT00220766   Canada;United States;
Donor peripheral blood stem cells.   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States;
Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase   
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States;
EDS-EP dose range of ~14-22 mg DSP/infusion   
   Erydel
      2017   Phase 3   NCT02770807   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EDS-EP dose range of ~5-10 mg DSP/infusion   
   Erydel
      2017   Phase 3   NCT02770807   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells   
   Great Ormond Street Hospital for Children NHS Trust
      2012   Phase 1;Phase 2   EUCTR2010-024253-36-GB   United Kingdom;
EF1aS-ADA lentiviral vector transduced patient CD34+ cells   
   Great Ormond Street Hospital for Children NHS Trust
      2012   Phase 1;Phase 2   EUCTR2010-024253-36-GB   United Kingdom;
EP2006 (Filgrastim)   
   Sandoz GmbH
      2011   -   EUCTR2011-001118-32-DE   Germany;Sweden;
EZN-2279   
   Leadiant Biosciences, Inc.
      2014   Phase 3   NCT01420627   United States;
Efficacy of Gammagard subcutaneously at Week 12   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Efficacy of Gammagard subcutaneously at Week 24   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Efficacy of Gammagard subcutaneously at Week 36   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Efficacy of Gammagard subdermally at Week 12   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Efficacy of Gammagard subdermally at Week 24   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Efficacy of Gammagard subdermally at Week 36   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Eflornithine   
   Drugs for Neglected Diseases
      2012   Phase 2/Phase 3   NCT01685827   Central African Republic;Congo;Congo, The Democratic Republic of the;
      2004   Phase 3   NCT00146627   Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
Eflornithine plus Nifurtimox combination therapy   
   Epicentre
      2002   Phase 2/Phase 3   NCT00489658   Uganda;
Elapegademase-lvlr   
   Chiesi Farmaceutici S.p.A.
      2019   -   NCT03878069   United States;
Eltrombopag   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT04371939   Russian Federation;
Empagliflozin   
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium;
   Hong Kong Children's Hospital
      2021   -   NCT04986735   -
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 1   NCT05078879   United States;
Estradiolvalerat   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Etoposide   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Etoposide, cytarabine, mercaptopurine   
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States;
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 1/Phase 2   NCT01306019   United States;
FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML   
   Orchard Therapeutics (Europe) Ltd
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy;
Fansidar (pyrimethamine and sulfadoxine)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00013689   United States;
Fexinidazole   
   Drugs for Neglected Diseases
      2019   Phase 2/Phase 3   NCT03974178   Malawi;Uganda;
      2016   Phase 3   NCT03025789   Congo, The Democratic Republic of the;Guinea;
      2015   Phase 1   NCT02571062   France;
      2014   Phase 2/Phase 3   NCT02184689   Congo, The Democratic Republic of the;
      2014   Phase 2/Phase 3   NCT02169557   Congo, The Democratic Republic of the;
      2014   Phase 2   NCT02498782   Bolivia;
      2012   Phase 2/Phase 3   NCT01685827   Central African Republic;Congo;Congo, The Democratic Republic of the;
      2009   Phase 1   NCT00982904   France;
Fibrinogen (coagulation factorI)   
   CSL Behring GmbH
      2011   -   EUCTR2007-004088-22-DE   Germany;Italy;
Fibrinogen Concentrate from Human Plasma   
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon;
Filgrastim   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
   National Center for Research Resources (NCRR)
      1994   Phase 2   NCT00004787   -
Filgrastim Hexal   
   Sandoz GmbH
      2011   -   EUCTR2011-001118-32-DE   Germany;Sweden;
Filgrastim, Alemtuzumab   
   St. Jude Children's Research Hospital
      2004   Phase 1   NCT00152100   United States;
Flebogamma DIF   
   Instituto Grifols, S.A.
      2008   Phase 4   NCT00634569   United States;
Fludarabina Accord   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Fludarabine   
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States;
      2004   Phase 2   NCT00578643   United States;
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
   Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
      2015   -   JPRN-UMIN000019532   Japan;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2007   Phase 2/Phase 3   NCT00455312   United States;
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States;
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States;
   St. Jude Children's Research Hospital
      2021   Phase 1/Phase 2   NCT03597594   United States;
Fludarabine Phosphate   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
      2006   Phase 2   NCT00358657   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Fludarabine monophosphate   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
Fludarabine phosphate   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2005   Phase 1   NCT00295971   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Fludarabine, Busulfan, Thymoglobulin   
   The Korean Society of Pediatric Hematology Oncology
      2007   Phase 1/Phase 2   NCT00885833   Korea, Republic of;
Fludarabine, Melphalan, Thiotepa   
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States;
Fortecortin Inject 40 mg Amp.   
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2005-003201-81-DE   Germany;
G-CSF   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT04370795   United States;
      2014   Phase 2/Phase 3   NCT02231879   United States;
G-CSF for Conditioning before HSCT.   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 2   NCT03019809   Russian Federation;
G1XCG   
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany;
G1XCGD transduced CD34+ cells   
   GENETHON
      2013   -   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom;
   Genethon
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom;
GAMMAGARD LIQUID   
   Baxalta now part of Shire
      2017   Phase 3   NCT03277313   United States;
GAMUNEX-C   
   Grifols Therapeutics Inc.
      2011   Phase 4   NCT01465958   United States;
GTG003.08   
   GENETHON
      -   Phase 1;Phase 2   EUCTR2009-011152-22-FR   France;
GVHD Prophylaxis   
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States;
      2015   Phase 2   NCT02579967   United States;
Gadolinium For abdomen   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Gadolinium For lower back   
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States;
Gammagard S/D (Solvent/Detergent)   
   Baxalta now part of Shire
      2002   Phase 2   NCT00161993   Finland;Sweden;
Gammaglobulin   
   Federal University of São Paulo
      2002   -   NCT00661401   Brazil;
Gammanorm   
   Octapharma
      2014   Phase 4   NCT02180763   France;
Gammanorm 165 mg/mL   
   Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria
      2015   Phase 3;Phase 4   EUCTR2014-003746-27-GB   Australia;Germany;United Kingdom;
      2015   Phase 3;Phase 4   EUCTR2014-003746-27-DE   Australia;Germany;Italy;United Kingdom;
Gammaplex   
   Bio Products Laboratory
      2011   Phase 4   NCT01289847   Chile;Israel;United States;
   Bio Products Laboratory Limited
      -   -   EUCTR2011-005679-18-Outside-EU/EEA   Chile;United States;
Gammaplex ()   
   Bio Products Laboratory
      2014   Phase 3   NCT01963143   Hungary;United Kingdom;United States;
Gammaplex (Intravenous immunoglobulin)   
   Bio Products Laboratory
      2006   Phase 3   NCT00278954   United States;
Gammaplex 10   
   Bio Products Laboratory
      2014   Phase 3   NCT01963143   Hungary;United Kingdom;United States;
   Bio Products Laboratory Limited
      2014   Phase 3   EUCTR2013-002290-21-HU   Hungary;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002290-21-GB   Hungary;Israel;United Kingdom;United States;
Gamunex-C   
   Grifols Therapeutics LLC
      2020   Phase 3   NCT04561115   United States;
Gcsf   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT03547830   Russian Federation;
Gene Therapy Method for CGD   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1995   Phase 1   NCT00001476   United States;
Gene transfer   
   David Williams
      2010   Phase 1/Phase 2   NCT01129544   United States;
Gene-Transduced Autologous CD34+ Stem Cells   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00028236   United States;
Generic Syringe then Chrono Super PID-Gammanorm   
   Octapharma
      2015   Phase 4   NCT02503293   Australia;Germany;Italy;United Kingdom;
Genetically modified autologous blood stem cells   
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany;
Glycolic acid   
   University of Pennsylvania
      2009   -   NCT01289171   Botswana;
Glycosade   
   John Mitchell
      2013   -   NCT02054832   Canada;
Gold   
   Chengdu Women's and Children's Center Hospital
      2021   Phase 0   ChiCTR2100043049   China;
   Children's Hospital of Chongqing Medical University
      2020   Phase 0   ChiCTR2000032139   China;
Gp91 Grans   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1   NCT05189925   United States;
Granulocyte colony stimulating factor (G-CSF)   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
HTLP   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 1;Phase 2   EUCTR2018-001029-14-FR   France;
HUMAN NORMAL IMMUNOGLOBULIN (IV)   
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States;
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE   
   LFB BIOTECHNOLOGIES
      2013   Phase 3   EUCTR2010-023483-41-FR   France;Hungary;
      2011   -   EUCTR2010-023483-41-HU   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
      2009   -   EUCTR2009-012036-32-FR   France;
      -   -   EUCTR2010-023483-41-Outside-EU/EEA   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
Haemocomplettan P   
   CSL Behring GmbH
      2007   -   EUCTR2006-006023-39-IT   Italy;
Haemocomplettan(R) P 1g/2g   
   CSL Behring GmbH
      2011   -   EUCTR2007-004088-22-DE   Germany;Italy;
Haplo BM with T cell depletion   
   Neena Kapoor, M.D.
      2007   Phase 1/Phase 2   NCT02127892   United States;
Haploidentical Hematopoietic Cell Transplantation   
   Johns Hopkins All Children's Hospital
      2020   Phase 2   NCT04414046   United States;
Hematopoetic Stem Cell Transplantation   
   University of Pittsburgh
      2012   -   NCT03333200   United States;
Hematopoietic Stem Cell Transplant   
   Medical College of Wisconsin
      2013   Phase 2   NCT01998633   Canada;United States;
Hematopoietic stem cell transplantation   
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States;
Hizentra   
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States;
   University of South Florida
      2010   -   NCT01354587   United States;
Hizentra®   
   CSL Behring
      -   -   EUCTR2014-003609-14-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-003608-61-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-003409-13-Outside-EU/EEA   Japan;
   CSL Behring AG
      2008   Phase 3   EUCTR2008-000830-30-GB   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
      -   -   EUCTR2014-003607-30-Outside-EU/EEA   United States;
      -   -   EUCTR2014-003605-15-Outside-EU/EEA   United States;
Horse -Anti-thymocyte   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT04370795   United States;
Human Fibrinogen Concentrate   
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon;
Human Immunglobulin G (IgG)   
   CSL Behring AG
      2007   Phase 3   EUCTR2006-006745-13-GB   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-006745-13-FR   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-006745-13-ES   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006745-13-SE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006745-13-DE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Human Immunoglobulin   
   KEDRION S.P.A
      2021   Phase 3   EUCTR2020-001496-32-PT   Hungary;Italy;Portugal;Russian Federation;Slovakia;
      2020   Phase 3   EUCTR2020-001496-32-SK   Hungary;Italy;Portugal;Russian Federation;Slovakia;
      2020   Phase 3   EUCTR2020-001496-32-HU   Hungary;Italy;Portugal;Russian Federation;Slovakia;
Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)   
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01412385   Austria;Germany;Hungary;Sweden;United Kingdom;
Human Normal Immunoglobulin G (IgG > purity)   
   CSL Behring AG
      -   -   EUCTR2014-003772-23-Outside-EU/EEA   United States;
Human Normal Immunoglobulin for Subcutaneous Administration   
   CSL Behring
      2006   Phase 3   NCT00419341   United States;
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)   
   CSL Behring
      2007   Phase 3   NCT00542997   France;Germany;Italy;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
Human Normal Immunoglobulin for subcutaneous administration   
   LFB Biotechnologies
      2014   -   EUCTR2013-000620-34-GB   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-IT   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-HU   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-DE   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Human T Lymphoid Progenitor (HTLP) injection   
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 1/Phase 2   NCT03879876   France;
Human normal immunoglobulin   
   UMC Utrecht
      2021   Phase 4   EUCTR2021-005001-26-NL   Netherlands;
Human normal immunoglobulin (IVIg)   
   Biotest AG
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary;
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary;
Human normal immunoglobulin (subcutaneous)   
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States;
Human normal immunoglobulin for intravenous administration   
   LFB SA
      2007   -   EUCTR2007-001410-17-FR   France;
Human normal immunoglobulin for intravenous use (IVIG)   
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary;
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary;
HyQvia 100 mg/ml solution for infusion for subcutaneous use   
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Hydroxyurea   
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States;
I10E   
   LFB BIOTECHNOLOGIES
      2013   Phase 3   EUCTR2010-023483-41-FR   France;Hungary;
      2011   -   EUCTR2010-023483-41-HU   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
      -   -   EUCTR2010-023483-41-Outside-EU/EEA   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
IB 1001   
   IntraBio Ltd.
      2019   Phase 2   EUCTR2018-004407-39-GB   Germany;United Kingdom;United States;
IB1001   
   IntraBio Inc
      2020   Phase 2   NCT03759678   Germany;Spain;United Kingdom;United States;
   IntraBio Ltd
      2020   Phase 2   EUCTR2018-004407-39-DE   Germany;Spain;United Kingdom;United States;
IFN-gamma   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2010   Phase 4   NCT01147042   United States;
IGIV,   
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IGIV-C   
   Grifols Therapeutics LLC
      2016   Phase 3   NCT02604810   Canada;United States;
IGNG   
   LFB BIOTECHNOLOGIES
      2009   -   EUCTR2009-012036-32-FR   France;
   LFB SA
      2007   -   EUCTR2007-001410-17-FR   France;
IGSC   
   Grifols Therapeutics LLC
      2021   Phase 4   NCT04566692   United States;
      2016   Phase 3   NCT02806986   Australia;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   NCT02604810   Canada;United States;
IGSC daily push versus 2 times per week pump   
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States;
IGSC daily push versus every 2 weeks pump   
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States;
IGSC daily push versus once a week pump   
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States;
IGSC infusion   
   Takeda
      2021   Phase 3   NCT04842643   Japan;
IGSC,   
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IMMUNOGLOBULIN G   
   CSL Behring
      2008   Phase 3   EUCTR2006-006745-13-PL   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
   OCTAPHARMA AG
      2012   -   EUCTR2012-000792-16-HU   Czech Republic;Germany;Hungary;
      2012   -   EUCTR2012-000792-16-DE   Czech Republic;Germany;Hungary;
      2012   -   EUCTR2012-000792-16-CZ   Czech Republic;Germany;Hungary;
   Octapharma AG
      -   -   EUCTR2011-005015-82-Outside-EU/EEA   United States;
IMMUNOGLOBULINA UMANA NORMALE   
   KEDRION S.P.A
      2020   Phase 3   EUCTR2020-001496-32-IT   Hungary;Italy;Portugal;Slovakia;
IV treatment with IGSC,   
   Baxalta now part of Shire
      2010   Phase 3   NCT01175213   United States;
IVIG   
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands;
IVIG-PEG   
   Grifols Therapeutics LLC
      2020   Phase 3   NCT04561115   United States;
Ibuprofen   
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set   
   Kedrion SpA
      2013   Phase 3   EUCTR2013-000961-36-DE   Germany;Italy;
IgG Next Generation   
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States;
IgG Next Generation (BT595)   
   Biotest
      2016   Phase 3   NCT02810444   Germany;Hungary;Russian Federation;Spain;United States;
IgHy10   
   University Hospital, Lille
      2016   Phase 4   NCT02881437   France;
IgNextGen   
   CSL Limited
      2007   Phase 3   NCT00391131   Australia;New Zealand;
IgPro10   
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan;
IgPro20   
   CSL Behring
      2017   Phase 4   NCT03033745   Canada;United States;
      2008   Phase 3   NCT00751621   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 3   NCT00719680   United States;
      2008   Phase 3   EUCTR2006-006745-13-PL   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
   CSL Behring AG
      2008   Phase 3   EUCTR2008-000830-30-GB   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 3   EUCTR2008-000830-30-FR   France;Germany;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000830-30-SE   France;Germany;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000830-30-ES   France;Germany;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000830-30-DE   France;Germany;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-006745-13-GB   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-006745-13-FR   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-006745-13-ES   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006745-13-SE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006745-13-DE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
      -   -   EUCTR2014-003607-30-Outside-EU/EEA   United States;
   CSL Behring AG (casa madre)
      2007   -   EUCTR2006-006745-13-IT   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States;
Immune Globulin Infusion (Human),   
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01485796   United States;
Immune Globulin Intravenous (Human)   
   Grifols Therapeutics Inc.
      2006   Phase 2   NCT00389324   Canada;United States;
Immune Globulin Intravenous (Human) Liquid, IVIG-SN™   
   Green Cross Corporation
      2011   Phase 3   NCT01406470   Canada;United States;
Immune Globulin Intravenous (Human),   
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01412385   Austria;Germany;Hungary;Sweden;United Kingdom;
      2007   Phase 2/Phase 3   NCT00546871   United States;
      2002   Phase 3   NCT00157079   United States;
Immune Globulin Intravenous (Human), Solution   
   Baxalta now part of Shire
      2013   Phase 2/Phase 3   NCT01218438   Canada;United States;
Immune Globulin Intravenous (Human), TVR (Triple Virally Reduced) Solution   
   Baxalta now part of Shire
      2002   Phase 2   NCT00161993   Finland;Sweden;
Immune Globulin Intravenous (IGIV)   
   Baxalta now part of Shire
      2020   Phase 3   NCT04346108   Japan;
Immune Globulin Intravenous [Human], Caprylate/Chromatography Purified   
   Grifols Therapeutics Inc.
      2002   Phase 3   NCT00220766   Canada;United States;
Immune Globulin Subcutaneos,   
   Baxter Innovations GmbH
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human) (SCIG)   
   CSL Behring
      2010   Phase 3   NCT01199705   Japan;
Immune Globulin Subcutaneous (Human),   
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01412385   Austria;Germany;Hungary;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human), , Caprylate/Chromatography Purified   
   Grifols Therapeutics Inc.
      2017   Phase 3   EUCTR2015-003290-15-HU   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-GB   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-FR   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-ES   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-DE   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-CZ   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      -   Phase 3   EUCTR2015-003290-15-PL   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Caprylate/Chromatography Purified (IGSC )   
   Grifols Therapeutics Inc.
      2017   Phase 3   EUCTR2015-003290-15-HU   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-GB   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-FR   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-ES   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-DE   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
      2016   Phase 3   EUCTR2015-003290-15-CZ   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
      -   Phase 3   EUCTR2015-003290-15-PL   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Solution   
   Baxalta now part of Shire
      2013   Phase 2/Phase 3   NCT01218438   Canada;United States;
Immune Globulin Subcutaneous,   
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous, Solution (IGSC, )   
   Baxalta now part of Shire
      2020   Phase 3   NCT04346108   Japan;
Immune globulin subcutaneous (Human)   
   CSL Behring
      2011   Phase 3   NCT01461018   Japan;
      2011   Phase 3   NCT01458171   Japan;
Immune globulin subcutaneous (human)   
   CSL Behring AG
      2008   Phase 4   EUCTR2006-006522-25-GR   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   Phase 4   EUCTR2006-006522-25-GB   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   Phase 4   EUCTR2006-006522-25-ES   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006522-25-DE   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006522-25-BE   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunglobulin (human)   
   CSL Behring AG
      2007   -   EUCTR2006-006522-25-IT   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunoglobulin G   
   OCTAPHARMA AG
      2010   -   EUCTR2009-011434-10-DE   Germany;
      -   -   EUCTR2009-011434-10-Outside-EU/EEA   United States;
Immunoglobulin G (Ig NextGen )   
   CSL Limited
      2008   Phase 3   NCT00680446   Australia;New Zealand;
Immunoglobulin intravenous (human)   
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan;
Immunoglobulins Intravenous (Human)   
   CSL Behring
      2005   Phase 3   NCT00322556   United States;
      2004   Phase 3   NCT00168025   -
      2004   Phase 3   NCT00168012   -
Immunoglobulins, normal human   
   CSL Behring AG (casa madre)
      2007   -   EUCTR2006-006745-13-IT   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Immunological diagnosis tests   
   University Hospital, Lille
      2015   -   NCT02972281   France;
Immunosuppression Only Conditioning   
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States;
Immunosuppression Only Conditioning -Closed with amendment L   
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States;
In vitro-treated peripheral blood stem cell transplantation   
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States;
Increlex   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 1/Phase 2   NCT00490100   United States;
Infliximab   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 1/Phase 2   NCT00325078   United States;
Infusion of autologous EFS-ADA LV CD34+ (OTL-101)   
   Orchard Therapeutics
      2013   Phase 1/Phase 2   NCT01852071   United States;
Infusion of autologous EFS-ADA LV CD34+ cells   
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom;
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)   
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom;
   Orchard Therapeutics
      2016   Phase 1/Phase 2   NCT02999984   United States;
Interferon-gamma   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1992   Phase 4   NCT00001317   United States;
Intratect   
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary;
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary;
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary;
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary;
Intravenous immunoglobulin infusion   
   Sanquin
      2013   Phase 3   NCT01985373   Netherlands;
Intravenous infusion of transduced cells   
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2003   Phase 1/Phase 2   NCT01279720   United Kingdom;
Isolex 300i Magnetic Cell Selector   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1995   Phase 1   NCT00001476   United States;
Itraconazole   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1991   Phase 2   NCT00001280   United States;
Jardiance   
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium;
KIOVIG   
   Baxalta now part of Shire
      2017   Phase 4   NCT03116347   Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
KIOVIG 100 mg/ml solution for infusion   
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
KIg10   
   KEDRION S.P.A
      2021   Phase 3   EUCTR2020-001496-32-PT   Hungary;Italy;Portugal;Russian Federation;Slovakia;
      2020   Phase 3   EUCTR2020-001496-32-SK   Hungary;Italy;Portugal;Russian Federation;Slovakia;
      2020   Phase 3   EUCTR2020-001496-32-IT   Hungary;Italy;Portugal;Slovakia;
      2020   Phase 3   EUCTR2020-001496-32-HU   Hungary;Italy;Portugal;Russian Federation;Slovakia;
KLH   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States;
KVD824   
   KalVista Pharmaceuticals, Ltd.
      2021   Phase 2   NCT05055258   Australia;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;Puerto Rico;United Kingdom;United States;
KVD824 300 mg Compresse a rilascio modificato   
   KalVista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 300 mg Modified Release Tablets   
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 hydrochloride   
   KalVista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD900   
   KalVista Pharmaceuticals, Ltd.
      2022   Phase 3   NCT05259917   -
      2019   Phase 2   NCT04208412   Austria;Czechia;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
KVD900 100 mg Film Coated Tablet   
   KalVista Pharmaceuticals Ltd
      2019   Phase 2   EUCTR2018-004489-32-IT   Austria;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-GB   Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
   KalVista Pharmaceuticals Ltd.
      2019   Phase 2   EUCTR2018-004489-32-PL   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-NL   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-HU   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-004489-32-DE   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-AT   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Kedrion IVIG   
   Kedrion S.p.A.
      2021   Phase 3   NCT04944979   Hungary;Italy;Slovakia;
      2019   Phase 3   NCT03961009   Canada;United States;
      2012   Phase 3   NCT01581593   Canada;United States;
Kineret   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2015   Early Phase 1   NCT04136028   Russian Federation;
L-Arginin-hydrochlorid-einmolar Fresenius   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
L-fucose   
   Orpha Labs
      2012   Phase 1/Phase 2   NCT03354533   -
LADICell   
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States;
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain;
LDT   
   Progenity, Inc.
      2015   -   NCT02787486   United States;
LFB-IgSC   
   LFB Biotechnologies
      2014   -   EUCTR2013-000620-34-GB   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-IT   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-HU   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2013-000620-34-DE   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Lemtrada   
   Karolinska Universitetssjukhuset
      2018   Phase 2   EUCTR2018-001489-41-SE   Sweden;United States;
Leniolisib   
   NOVARTIS PHARMA SERVICES AG
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IT   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
   Novartis Pharma Services AG
      2021   Phase 2;Phase 3   EUCTR2016-000468-41-FR   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2016-000468-41-GB   Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-NL   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-CZ   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
   Pharming Technologies B.V.
      -   Phase 2;Phase 3   EUCTR2016-000468-41-DE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Lentiviral G1XCGD Gene Therapy   
   University of California, Los Angeles
      2015   Phase 1/Phase 2   NCT02234934   United States;
Lentiviral vector transduced CD34+ cells   
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1   NCT03601286   United Kingdom;
MABTHERA - 2 FIALE 100 MG 10 ML   
   Orchard Therapeutics (Europe) Ltd
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy;
MBM-01   
   Matrix Biomed, Inc.
      2021   Phase 2   NCT04887311   United States;
MCTLs   
   Catherine Bollard
      2014   Phase 1   NCT02510404   United States;
MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO   
   Orchard Therapeutics (Europe) Ltd
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy;
MYELOSTIM   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO + SIRINGA PRERIEMPITA SOLVENTE 1 ML   
   Orchard Therapeutics (Europe) Ltd
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy;
MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion   
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion   
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
MabThera   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Mavorixafor   
   X4 PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001153-10-IT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   X4 Pharmaceuticals
      2020   Phase 1   NCT04154488   United States;
      2019   Phase 3   NCT03995108   Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United States;
   X4 Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-001153-10-PL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-NL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-HU   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-GB   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-FR   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-ES   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-DE   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-AT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001153-10-DK   Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d   
   Epicentre
      2001   Phase 3   NCT00330148   Uganda;
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d   
   Epicentre
      2001   Phase 3   NCT00330148   Uganda;
Melphalan   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Metformin   
   NHS Tayside
      2016   Phase 4   NCT02733679   United Kingdom;
Methotrexate   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Methylprednisolone   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Methylprednisolone or Prednisolone   
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
Miltenyi CliniMACS   
   St. Jude Children's Research Hospital
      2004   Phase 1   NCT00152100   United States;
Miltenyi CliniMACS selection system   
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States;
Mozobil   
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy;
Mozobil 20mg/mL vial (injectable solution for subcutaneous use)   
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
Mozobil 20mg/mL vial (injectable solution, subcutaneous use)   
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
Mozobil,   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Mycophenolate mofetil   
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Mycophenolate mofetil (MMF)   
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
Myeloablative Conditioning-Closed with amendment L   
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States;
Myeloablative Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Myelostim   
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy;
N-Acetyl-L-Leucine   
   IntraBio Ltd.
      2019   Phase 2   EUCTR2018-004407-39-GB   Germany;United Kingdom;United States;
NDV-3A   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2016   Phase 2   NCT02996448   United States;
Nanogam 100 mg/ml   
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands;
Nanogam® 50 mg/ml   
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands;
Neopterin   
   Institut de Recherche pour le Developpement
      2017   -   NCT03112655   Congo, The Democratic Republic of the;
NewGam   
   OCTAPHARMA AG
      2010   -   EUCTR2009-011434-10-DE   Germany;
      -   -   EUCTR2009-011434-10-Outside-EU/EEA   United States;
   Octapharma
      2011   Phase 3   NCT01313507   United States;
      2010   Phase 3   NCT01012323   United States;
Newnorm   
   Octapharma
      2021   Phase 3   NCT04640142   Germany;Poland;Slovakia;Ukraine;United States;
   Octapharma Pharmazeutika Prod.Ges.m.b.H
      2021   Phase 1;Phase 3   EUCTR2020-004734-37-DE   Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
      -   Phase 1;Phase 3   EUCTR2020-004734-37-SK   Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
      -   Phase 1;Phase 3   EUCTR2020-004734-37-PL   Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
Nicotinamide ribonucleoside   
   University Hospital, Akershus
      2019   Phase 2   NCT04870866   Norway;
Nifurtimox   
   Drugs for Neglected Diseases
      2012   Phase 2/Phase 3   NCT01685827   Central African Republic;Congo;Congo, The Democratic Republic of the;
      2004   Phase 3   NCT00146627   Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
   Universidad Autónoma de Bucaramanga
      2015   Phase 2/Phase 3   NCT02369978   Colombia;
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d   
   Epicentre
      2001   Phase 3   NCT00330148   Uganda;
Nifurtimox-Eflronithine Combination Treatment (NECT)   
   Drugs for Neglected Diseases
      2009   Phase 4   NCT00906880   Congo;
None   
   KalVista Pharmaceuticals Ltd
      2019   Phase 2   EUCTR2018-004489-32-GB   Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
   KalVista Pharmaceuticals Ltd.
      2019   Phase 2   EUCTR2018-004489-32-PL   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-NL   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-HU   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-004489-32-DE   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004489-32-AT   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
      1997   Phase 1   NCT00008450   United States;
Normal human immunoglobulin G   
   CSL Behring AG
      2008   -   EUCTR2008-000830-30-SE   France;Germany;Spain;Sweden;United Kingdom;
Norovirus -specific T-cell (NST) therapy   
   Children's National Research Institute
      2020   Phase 1   NCT04691622   United States;
Noxafil 40 mg/ml oral solution   
   Radboud University Nijmegen Medical Centre
      2009   -   EUCTR2008-004518-28-GB   Netherlands;United Kingdom;
      2008   -   EUCTR2008-004518-28-NL   Netherlands;United Kingdom;
NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
OCTA-C1-INH   
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2020   Phase 2   EUCTR2019-001693-28-DE   Belarus;Germany;Russian Federation;Ukraine;
OCTAGAM 50 mg/ml oldatos infúzió   
   OCTAPHARMA AG
      2012   -   EUCTR2012-000792-16-HU   Czech Republic;Germany;Hungary;
ORENCIA® 125 mg solution for injection in pre-filled syringe   
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany;
OTL-101   
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom;
   Orchard Therapeutics
      2019   Phase 2/Phase 3   NCT04140539   United States;
OTL-103 Dispersion for Infusion   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Octagam   
   OCTAPHARMA AG
      2012   -   EUCTR2012-000792-16-DE   Czech Republic;Germany;Hungary;
   Octapharma
      2009   Phase 3   NCT00811174   Austria;
   Octapharma AG
      2010   Phase 3   EUCTR2007-002611-27-GB   France;Germany;United Kingdom;
      2010   -   EUCTR2007-002611-27-FR   France;United Kingdom;
      2008   -   EUCTR2007-002611-27-DE   France;Germany;United Kingdom;
Octanorm   
   Octapharma
      2017   Phase 3   NCT03988426   Russian Federation;
      2016   Phase 3   NCT03907241   Canada;United States;
      2016   Phase 3   NCT02627300   Canada;United States;
      2014   Phase 3   NCT01888484   Canada;Czech Republic;Czechia;Hungary;Poland;Russian Federation;Slovakia;United States;
   Octapharma Pharmazeutika Prod.Ges.m.b.H
      2017   Phase 1;Phase 3   EUCTR2013-003877-87-SK   Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia;United States;
      2015   Phase 3   EUCTR2013-003877-87-PL   Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
      2014   Phase 3   EUCTR2013-003877-87-HU   Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
      2014   Phase 1;Phase 3   EUCTR2013-003877-87-CZ   Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
Omalizumab (Xolair)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 1   NCT00260702   United States;
Other hematological Agents   
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy;
Ovastat 1000 (Treosulfan injection)   
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland;
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland;
   medac GmbH
      2015   -   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland;
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 1000 mg, powder for solution for infusion   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 (Treosulfan injection)   
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland;
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland;
   medac GmbH
      2015   -   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland;
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 mg, powder for solution for infusion   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland;
PEG-ADA ERT   
   Orchard Therapeutics
      2016   Phase 1/Phase 2   NCT02999984   United States;
      2013   Phase 1/Phase 2   NCT01852071   United States;
PEG-interleukin-2   
   Mount Sinai School of Medicine
      1997   -   NCT00004695   -
PHA-022121   
   Pharvaris Netherlands B.V.
      2022   Phase 2   NCT05047185   Canada;United Kingdom;United States;
      2021   Phase 2   NCT04618211   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Pharvaris Netherlands BV
      2022   Phase 2   EUCTR2021-000227-13-PL   Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-000227-13-BG   Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-PL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-NL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-HU   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
      2021   Phase 2   EUCTR2020-003445-11-DE   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-BG   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-003445-11-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
      -   Phase 2   EUCTR2020-003445-11-CZ   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PHVS416   
   Pharvaris Netherlands BV
      2022   Phase 2   EUCTR2021-000227-13-PL   Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-000227-13-BG   Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-PL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-NL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-HU   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
      2021   Phase 2   EUCTR2020-003445-11-DE   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003445-11-BG   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-003445-11-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
      -   Phase 2   EUCTR2020-003445-11-CZ   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PID   
   Children's Hospital of Chongqing Medical University
      2020   Phase 0   ChiCTR2000032139   China;
PNEUMO 23   
   Inserm
      2009   -   EUCTR2007-003235-23-FR   France;
PREVENAR   
   Inserm
      2009   -   EUCTR2007-003235-23-FR   France;
PROLEUKIN® S   
   Universitätsklinikum Freiburg
      2016   Phase 2   EUCTR2015-003369-27-DE   Germany;
PSRS11.EFS.IL2RG.pre* retroviral vector transduce   
   Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
      2010   Phase 1;Phase 2   EUCTR2007-000684-16-GB   United Kingdom;
PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells   
   Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
      2010   Phase 1;Phase 2   EUCTR2007-000684-16-GB   United Kingdom;
PTH 1-34   
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 3   NCT00395538   Austria;Italy;United States;
Palifermin   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 1/Phase 2   NCT03315078   United States;
      2012   Phase 1/Phase 2   NCT01306019   United States;
Pantoprazolo 20 mg gastro-resistant tablets   
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
Peg-Ada   
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom;
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom;
Pentamidine   
   Immtech Pharmaceuticals, Inc
      2003   Phase 2   NCT00803933   Congo;
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Peripheral blood stem cell transplantation   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Peripheral blood stem cells   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2015   Phase 1/Phase 2   NCT02629120   United States;
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Early Phase 1   NCT00394316   United States;
Pioglitazone   
   Children's Hospital of Fudan University
      2017   Phase 1/Phase 2   NCT03080480   China;
   NHS Tayside
      2016   Phase 4   NCT02733679   United Kingdom;
Plerixafor   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT03547830   Russian Federation;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 2/Phase 3   NCT02231879   United States;
   Ospedale San Raffaele
      2015   -   EUCTR2015-002356-27-IT   Italy;
Plerixafor for Conditioning before HSCT.   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 2   NCT03019809   Russian Federation;
PnCJ PPS   
   Institut National de la Santé Et de la Recherche Médicale, France
      2009   Phase 2   NCT01489618   France;
Pneumovax® (pneumococcal polysaccharide vaccine)   
   Sheba Medical Center
      2010   -   NCT01075438   Israel;
Polyclonal IgG   
   Federico II University
      2010   -   NCT03534479   Italy;
Posaconazole (PSZ)   
   Radboud University
      2009   Phase 2   NCT00799071   Netherlands;United Kingdom;
Prednisone   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Prevenar   
   Great Ormond Street Hospital
      2005   Phase 4   EUCTR2005-004122-70-GB   United Kingdom;
Prevenar® (7-valent pneumococcal conjugate vaccine)   
   Sheba Medical Center
      2010   -   NCT01075438   Israel;
Privigen   
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan;
Privigen®   
   CSL Behring AG
      -   -   EUCTR2014-003772-23-Outside-EU/EEA   United States;
Progynova 21 mite   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Promacta   
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00909363   United States;
Prometic's Immune Globulin Intravenous   
   Prometic Biotherapeutics, Inc.
      2016   Phase 3   NCT02269163   United States;
Purified Vero Cell Vaccine)   
   Chulalongkorn University
      2015   Phase 4   NCT02490956   Thailand;
Pyrimethamine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2003   Phase 1   NCT00065390   United States;
R-hIL-18BP   
   AB2 Bio Ltd.
      2019   Phase 3   EUCTR2018-003297-27-DE   Canada;Germany;United States;
      -   Phase 3   EUCTR2018-003199-10-DE   Canada;Germany;United States;
RAG1 LV CD34+ cells   
   Leiden University Medical Center
      2020   Phase 1;Phase 2   EUCTR2019-002343-14-NL   Netherlands;
RI-002   
   ADMA Biologics, Inc.
      2014   Phase 3   NCT01814800   United States;
RP-L201   
   Rocket Pharmaceuticals Inc.
      2019   Phase 1/Phase 2   NCT03812263   Spain;United Kingdom;United States;
      2019   Phase 1   NCT03825783   Spain;
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States;
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain;
Rabbit anti-thymocyte globulin   
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
Ranitidine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00527878   United States;
Recombinant Human Hyaluronidase (rHuPH20)   
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
Recombinant human hyaluronidase   
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01485796   United States;
   Nishizawa Atsushi
      2022   Phase 3   JPRN-jRCT2031210457   Japan;
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)   
   Baxalta now part of Shire
      2008   Phase 3   NCT00814320   Canada;United States;
Recombinant human hyaluronidase + immune globulin intravenous   
   Baxalta now part of Shire
      2006   Phase 1/Phase 2   NCT00782106   United States;
Reduced Intensity Conditioning   
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States;
      2015   Phase 2   NCT02579967   United States;
Reduced Intensity Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Reduced Toxicity Ablative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Retroviral SF71-gp91phox transduced CD34+ cells   
   Johann Wolfgang Goethe University Hospitals
      2004   Phase 1/Phase 2   NCT00564759   Germany;
Retrovirus-mediated gene transfer   
   David Williams
      2011   Phase 1/Phase 2   NCT01410825   United States;
RhuCD40L   
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States;
Rifaximin   
   Oslo University Hospital
      2013   Phase 4   NCT01946906   Norway;
Rimiducid   
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom;
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
Rituximab   
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan;
Rituximab (RTX) and Azathioprine (AZA)   
   Medical College of Wisconsin
      2016   Phase 2   NCT02789397   -
Rivogenlecleucel   
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom;
Romiplostim   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT04371939   Russian Federation;
      2012   -   NCT04350164   Russian Federation;
SC treatment with IGSC, with rHuPH20 followed by IV/IGSC, only (safety)   
   Baxalta now part of Shire
      2010   Phase 3   NCT01175213   United States;
SC treatment with IGSC, with rHuPH20 followed by SC/IGSC, only (safety)   
   Baxalta now part of Shire
      2010   Phase 3   NCT01175213   United States;
SCID screening   
   Nantes University Hospital
      2014   -   NCT02244450   France;
SCYX-7158   
   Drugs for Neglected Diseases
      2012   Phase 1   NCT01533961   France;
STA-5326   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 1   NCT00263237   United States;
STRIMVELIS   
   Orchard Therapeutics
      2018   -   NCT03232203   Italy;
SUBCUVIA   
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Sirolimus   
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   Imai Kohsuke
      2022   Phase 2   JPRN-jRCT2031210309   Japan;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT04370795   United States;
      2019   Early Phase 1   NCT03910452   United States;
      2015   Phase 1/Phase 2   NCT02629120   United States;
      2014   Phase 1/Phase 2   NCT02282904   United States;
   University of California, San Francisco
      2014   Phase 2   NCT02177760   United States;
Sodium chloride   
   AB2 Bio Ltd.
      2017   Phase 3   NCT03113760   Canada;Germany;United States;
Somatic gene-therapy by X-CGD   
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany;
Somatotropin   
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany;
Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate   
   Johann Wolfgang Goethe University Hospitals
      2010   Phase 4   NCT01052623   Germany;
Stelara (ustekinumab)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2015   Phase 1/Phase 2   NCT02199496   United States;
Stem Cell Infusion   
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States;
Stem Cell Transplant   
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
Stem Cell Transplantation   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
      2007   Phase 2/Phase 3   NCT00455312   United States;
Stem cell infusion   
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States;
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Stem cell transplant   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
   St. Jude Children's Research Hospital
      2004   Phase 1   NCT00152100   United States;
Strimvelis   
   Orchard Therapeutics (Europe) Ltd
      2017   Phase 4   EUCTR2017-001731-39-IT   Italy;Switzerland;Turkey;
Subgam   
   Bio Products Laboratory
      2015   Phase 3   NCT01884311   United States;
Suspension of autologous CD34+cells transduced with the G1XCGD viral vector   
   GENETHON
      2013   -   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom;
   Genethon
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom;
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 3   NCT00023192   United States;
TAK-771   
   Takeda
      2022   Phase 3   NCT05150340   Japan;
TBX-1400   
   Taiga Biotechnologies, Inc.
      2021   Phase 1   NCT02860559   Israel;
TCR alfa beta T cell depletion   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2012   Phase 2/Phase 3   NCT02327351   Russian Federation;
TYF-IL-2Rg gene-modified autologous stem cells   
   Shenzhen Geno-Immune Medical Institute
      2017   Phase 1/Phase 2   NCT03217617   China;
Tabelecleucel   
   Atara Biotherapeutics
      2021   Phase 2   NCT04554914   Austria;Belgium;France;Italy;Spain;United Kingdom;United States;
      2016   -   NCT02822495   United States;
Tablets Fexinidazole   
   Drugs for Neglected Diseases
      2011   Phase 1   NCT01483170   France;
Tacrolimus   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
      2006   Phase 2   NCT00358657   United States;
   M. Louise Markert
      2010   -   NCT01220531   United States;
      2005   Phase 1/Phase 2   NCT00579527   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Tacrolimus (Tacro)   
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States;
Tadekinig alfa   
   AB2 Bio Ltd.
      2018   Phase 3   NCT03512314   Canada;Germany;United States;
      2017   Phase 3   NCT03113760   Canada;Germany;United States;
Thalidomide   
   Kawai Toshinao
      2017   Phase 2-3   JPRN-jRCT2031200236   Japan;
   National Center for Child Heath and Development
      2017   -   JPRN-UMIN000029324   Japan;
      2012   -   JPRN-UMIN000009370   Japan;
Therapeutic allogeneic lymphocytes   
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States;
There is no recommended INN   
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom;
Thiotepa   
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States;
   St. Jude Children's Research Hospital
      2021   Phase 1/Phase 2   NCT03597594   United States;
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States;
Thiotepa--escalated dose   
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States;
Thiotepa--single daily dose   
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States;
Thymafalsin   
   Erasmus MC
      2022   Phase 2   EUCTR2021-003327-15-NL   Netherlands;
Thymus Tissue for Transplantation   
   M. Louise Markert
      2002   Phase 1   NCT00579709   United States;
Thymus/Parathyroid Transplantation   
   M. Louise Markert
      2005   Phase 1   NCT00566488   United States;
To be confirmed   
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
Total Body Irradiation   
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Total lymphoid irradiation   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
Traditional treatment of CGD and TB   
   Children's Hospital of Fudan University
      2019   Phase 2/Phase 3   NCT03984890   China;
Transduced Lymphocytes   
   National Human Genome Research Institute (NHGRI)
      1990   -   NCT00001255   United States;
Transplant Conditioning with Mobilization Only   
   University of California, San Francisco
      2010   Phase 2   NCT01182675   United States;
Transplant Conditioning with Mobilization and Alemtuzumab   
   University of California, San Francisco
      2010   Phase 2   NCT01182675   United States;
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan   
   Washington University School of Medicine
      2013   Phase 2   NCT01821781   United States;
Treosulfan   
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2020   Phase 2   NCT04400045   Russian Federation;
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   medac GmbH
      2015   Phase 2   NCT02349906   Austria;Czech Republic;Czechia;Germany;Italy;Poland;
Triheptanoin   
   The University of Queensland
      2022   Phase 2   NCT04513002   Australia;
Umbilical cord blood transplantation   
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Unrelated BM with T cell depletion   
   Neena Kapoor, M.D.
      2007   Phase 1/Phase 2   NCT02127892   United States;
Unrelated PBSC with T cell depletion   
   Neena Kapoor, M.D.
      2007   Phase 1/Phase 2   NCT02127892   United States;
Unrelated cord blood   
   Neena Kapoor, M.D.
      2007   Phase 1/Phase 2   NCT02127892   United States;
Ustekinumab   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2018   Phase 1/Phase 2   NCT03366142   United States;
VM106   
   Helixmith Co., Ltd.
      2007   Phase 1/Phase 2   NCT00778882   Korea, Republic of;
Valacyclovir   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2000   Phase 3   NCT00031486   Canada;Sweden;United Kingdom;United States;
Verorab® (PVRV   
   Chulalongkorn University
      2015   Phase 4   NCT02490956   Thailand;
Vigantol   
   Karolinska University Hospital
      2010   Phase 1/Phase 2   NCT01131858   Sweden;
Vinblastine, vincristine, prednisone, daunorubicin   
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States;
Vitamin B3   
   Radboud University
      2019   Phase 2   NCT03962114   Netherlands;
Vitamin D3   
   Children's Hospital of Fudan University
      2019   Phase 2/Phase 3   NCT03984890   China;
Vivaglobin   
   CSL Behring
      2007   Phase 4   NCT00520494   Belgium;Canada;Germany;Italy;Spain;
   CSL Behring AG
      2008   Phase 4   EUCTR2006-006522-25-GR   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   Phase 4   EUCTR2006-006522-25-GB   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   Phase 4   EUCTR2006-006522-25-ES   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006522-25-IT   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006522-25-DE   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006522-25-BE   Belgium;Germany;Greece;Italy;Spain;United Kingdom;
X4P-001   
   X4 PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001153-10-IT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   X4 Pharmaceuticals
      2016   Phase 2   NCT03005327   Australia;United States;
   X4 Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-001153-10-PL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-NL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-HU   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-GB   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-FR   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-ES   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-DE   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001153-10-AT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001153-10-DK   Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
XELJANZ (tofacitinib)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05104723   United States;
Xifaxan   
   Oslo University hospital
      2013   -   EUCTR2013-000883-27-NO   Norway;
Zadaxin   
   Erasmus MC
      2022   Phase 2   EUCTR2021-003327-15-NL   Netherlands;
Zarzio   
   Sandoz GmbH
      2012   Phase 4   EUCTR2011-001118-32-SE   Germany;Sweden;
Zoledronate   
   Department of Pediatrics, Tokyo Medical and Dental University
      2014   -   JPRN-UMIN000013102   Japan;